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Abstract: More than one third of individuals with chronic obstructive pulmonary disease 
(COPD) experience comorbid symptoms of depression and anxiety. This review aims to provide 
an overview of the burden of depression and anxiety in those with COPD and to outline the 
contemporary advances and challenges in the management of depression and anxiety in COPD. 
Symptoms of depression and anxiety in COPD lead to worse health outcomes, including impaired 
health-related quality of life and increased mortality risk. Depression and anxiety also increase 
health care utilization rates and costs. Although the quality of the data varies considerably, the 
cumulative evidence shows that complex interventions consisting of pulmonary rehabilitation 
interventions with or without psychological components improve symptoms of depression and 
anxiety in COPD. Cognitive behavioral therapy is also an effective intervention for manag-
ing depression in COPD, but treatment effects are small. Cognitive behavioral therapy could 
potentially lead to greater benefits in depression and anxiety in people with COPD if embedded 
in multidisciplinary collaborative care frameworks, but this hypothesis has not yet been empiri-
cally assessed. Mindfulness-based treatments are an alternative option for the management of 
depression and anxiety in people with long-term conditions, but their efficacy is unproven in 
COPD. Beyond pulmonary rehabilitation, the evidence about optimal approaches for manag-
ing depression and anxiety in COPD remains unclear and largely speculative. Future research 
to evaluate the effectiveness of novel and integrated care approaches for the management of 
depression and anxiety in COPD is warranted.
Keywords: chronic obstructive pulmonary disease, depression and anxiety, health outcomes, 
pulmonary rehabilitation, cognitive behavioral therapy, multidisciplinary case management
Introduction
Prevalence and symptoms of depression and anxiety
Depression is a common mental health problem accompanied by a high degree of 
emotional distress and functional impairment.1 The two main symptoms of major 
depression include depressed mood and loss of interest or pleasure in daily   activities. 
Additional symptoms of depression include fatigue or loss of energy, significant 
changes in weight, appetite and sleep, guilt/worthlessness, lack of concentration, 
pessimism about the future, and suicidality. According to the Fifth Edition of the 
Statistical Manual of Mental Disorders, a diagnosis of major depression is assigned 
if at least one of two main symptoms and five symptoms in total are present for at 
least 2 weeks and cause clinically significant impairment in social, occupational, or 
other important areas of functioning.2,3 Major depressive disorder accounted for 8.2% 
of years living with disability in 2010, making it the second leading direct cause of 
global disease burden.4International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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Anxiety is also a common mental health problem and 
is associated with physical and psychological discomfort. 
All the anxiety disorders share common symptoms, such 
as fear, anxiety, and avoidance. Other anxiety-related 
symptoms include fatigue, restlessness, irritability, sleep 
disturbances, reduced concentration and memory, and 
muscle tension.3 Among the anxiety disorders, the most 
common are specific or social phobias and generalized 
anxiety disorder.5
Depression and anxiety often co-occur; it is estimated 
that at least half of people with depression also have anxiety. 
In fact, there is evidence that a mixed state of depression 
and anxiety is more prevalent than depression alone.6 The 
prevalence of depression and anxiety is two to three times 
higher in people with chronic (long-term) medical condi-
tions.7 People with a long-term condition and depression/
anxiety have worse health status than people with depression/
anxiety alone, or people with any combination of long-term 
conditions without depression.8
Prevalence of depression  
and anxiety in COPD
A recent meta-analysis that included 39,587 individuals with 
COPD and 39,431 controls found that one in four COPD 
patients experienced clinically significant depressive symp-
toms compared with less than one in eight of the controls 
(24.6%, 95% confidence interval [CI] 20.0–28.6 versus 
11.7%, 95% CI 9.0–15.1).9 These estimates are consistent 
with the findings of previous qualitative and quantitative 
reviews that assessed the prevalence of depressive symptoms 
in COPD.10–12 Clinical anxiety has also been recognized as a 
significant problem in COPD, with an estimated prevalence 
of up to 40%.12,13 Additionally, COPD patients are ten times 
more likely to experience panic disorder or panic attacks 
compared with general population samples.14 Of note, the 
great variability of methods used to assess depression and 
anxiety in the literature makes it difficult to reach a consensus 
about the prevalence of depression and anxiety in COPD. 
Future research should quantify whether prevalence rates 
for depression and anxiety in COPD are significantly differ-
ent among samples identified by self-rated or standardized 
interview methods.
The causes of depression and anxiety in COPD are likely 
to be multifactorial, but importantly disease severity does 
not appear to affect the levels of anxiety and depression in 
COPD patients.15 Rather, subjective ratings of health-related 
quality of life (HRQoL), dyspnea, and reduced exercise 
capacity potentially underlie the development of symptoms of 
depression and anxiety in COPD.16,17 Additionally, depression 
and anxiety are more often reported in women than in men 
with COPD, but differences in perceived symptom control 
and severity of dyspnea symptoms appear to account for 
this finding.18,19 The meta-analysis by Zhang et al showed 
no differences in the prevalence of depression in COPD 
between studies of Western and non-Western populations.9 
However, there is evidence that certain subgroups of British 
South Asians have higher rates of depression, but it is not 
clear what contribution somatic, genetic, or lifestyle factors 
play in accounting for health differentials between different 
ethnic groups.20–22 Further research is needed to examine the 
effects of ethnicity and nationality on the prevalence rates of 
depression and anxiety in COPD.
Impact of depression and anxiety  
on health-related quality of life
HRQoL is a multifaceted concept that is uniquely linked to 
health or illness, and includes a number of distinct domains 
corresponding to the physical, social, and psychological 
impact of illness.23 A considerable number of published 
empirical studies and systematic reviews offer robust evi-
dence that symptoms of depression and anxiety are associated 
with poorer HRQoL in COPD.24–26 However, this evidence is 
mainly derived from cross-sectional studies, which preclude 
any temporal or causal inferences being made about the 
association between HRQoL and depression and anxiety in 
COPD. A recent systematic review by Blakemore et al has 
examined the longitudinal impact of depression and anxiety 
on HRQoL. This review found that both depression and anxi-
ety at baseline are significantly associated with worsening 
levels of HRQoL at 1 year follow-up (pooled r=0.48, 95% 
CI 0.37–0.57, P,0.001; pooled r=0.36, 95% CI 0.23–0.48, 
P,0.001; for depression and anxiety, respectively).27 The 
findings of this review suggest that HRQoL may be a 
worthwhile target for interventions aiming to improve the 
psychological health of people with COPD.27
Impact of depression and anxiety  
on health care utilization
Comorbid depression and anxiety in COPD is associated with 
a disproportionate increase in health care utilization rates 
and costs. A population-based study among people with six 
chronic conditions (including COPD) showed that comorbid 
depression doubled the likelihood of health care utilization, 
functional disability, and work absence.28 Similarly, a US 
study among a managed care population showed that COPD 
patients with comorbid depression were 77% more likely International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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to have a COPD-related hospitalization, 48% more likely 
to have an emergency room visit, and 60% more likely to 
have a hospitalization/emergency room visit compared with 
COPD patients without comorbid depression.29 Other stud-
ies in this area suggest that depression in COPD leads to 
excessive health care utilization rates and costs, including 
longer hospital stay after acute exacerbation,30 increased 
risk of exacerbation and hospital admission,31,32 and hospi-
tal readmission.33 Comorbid anxiety and panic disorder in 
COPD is also associated with increased risk of exacerbations, 
relapse within 1 month of receiving emergency treatment,34 
and hospital readmission.35
Evidence from systematic reviews and empirical stud-
ies suggests that the presence of mental health problems 
(including depression and anxiety) inflates the costs of care 
for long-term conditions by at least 45% after controlling 
for severity of physical illness.36–41 In COPD in particular, a 
recent study showed that comorbid depression and anxiety 
significantly inflated average annual all-cause health care 
costs ($23,759 versus $17,765 per patient, P,0.001) and 
COPD total health care costs ($3,185 versus $2,680 per 
patient; P,0.001).29 Moreover, Howard et al found that the 
addition of a psychological component in a breathlessness 
clinic for COPD led to savings of £837 per patient 6 months 
after the intervention (which were mainly attributed to lower 
emergency room visits and fewer hospital bed days).42
Impact of depression and anxiety  
on mortality in COPD
COPD is the fourth leading cause of morbidity worldwide 
and is expected to be the third leading cause of mortality by 
2020.43 The bulk of studies exploring mortality in patients 
with COPD have mainly focused on physiologic prognostic 
factors.44 In the past decade, an increasing number of prog-
nostic studies have indicated that mental health problems also 
contribute significantly to mortality risk in COPD. Depression 
is a particularly strong predictor for mortality in COPD (odds 
ratios ranging from 1.9 to 2.7)30,45,46 and its predictive ability 
persists over and above the effects of other prognostic factors, 
including physiological factors, demographic factors, and 
disease severity.47,48 Moreover, preliminary evidence suggests 
that depression and anxiety interact with other risk factors (eg, 
physiological factors and smoking) to produce stronger com-
bined effects on mortality risk in COPD.49 On these grounds, 
the risk for death in COPD might be better ascertained by the 
simultaneous consideration of physiological and psychologi-
cal prognostic factors and the awareness that the impact of 
these factors on mortality could be cumulative.
Managing depression and anxiety 
in COPD
There is a growing consensus in respiratory medicine that 
the therapeutic focus in COPD should move beyond disease 
modification and survival alone, and include assessment and 
improvement of patient-centered outcomes, including health 
status and psychological health.50,51 Likewise, in recognition 
of the increased health and economic burden associated with 
aging populations with long-term conditions, governments 
and policymakers are equally keen to promote approaches that 
integrate physical and mental health care, leading to improved 
patient outcomes, reduced unscheduled care, and reduced 
health care costs.52 In the UK, for example, the National 
Institute for Health and Care Excellence has published clinical 
guidelines that recommend the use of stepped approaches to 
psychological and/or pharmacological treatment of depres-
sion in adults in primary care;53 similar guidelines have 
been published to underpin comparable approaches for 
managing depression in people with long-term conditions.54 
  Treatments include psychological therapies based on a 
cognitive and behavioral framework with or without antide-
pressant   medication.55 But while there is good evidence that 
psychological therapies are as effective as antidepressants,56 
and that patients prefer psychological therapies,57 treatment 
of depression and anxiety in people with long-term condi-
tions is not as optimal as it could be. This is especially true 
in primary care where the majority of COPD patients are 
managed. Time-limited consultations that prioritize physical 
health mean that depression and anxiety remain underdetected 
and undertreated in people with COPD.58
Outside of general practice-led primary care, the most 
promising intervention to meet the challenges of managing 
depression in people with COPD is pulmonary rehabilitation. 
There is growing evidence that pulmonary rehabilitation 
can not only improve HRQoL and exercise capacity,59,60 
but depression and anxiety too.61 The next section of this 
overview offers a detailed summary of the comparative 
effectiveness of pulmonary rehabilitation and other non-
pharmacological interventions for managing depression in 
people with COPD.
Multidisciplinary pulmonary rehabilitation
Coventry et al recently conducted a systematic review with 
meta-analysis that examined the comparative effects of 
a broad range of psychological and/or lifestyle interven-
tions on depression and anxiety in COPD.62 Interventions 
were divided into four subgroups: cognitive behavioral 
therapy (CBT) interventions, multicomponent interventions International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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Table 1 Characteristics of the study populations
Reference Sample  
size
Mean 
age, years
Males 
(%)
COPD severity 
(GOLD stage)
Where  
recruited
Depressed  
at baseline
Anxious  
at baseline
Depression  
assessment
Anxiety 
assessment
Baseline mean (SD)  
depression score
Baseline mean (SD) 
anxiety score
Blumenthal  
et al86
158 50 44 Severe (stage 3) Secondary care No No BDI STAI I, 13.4 (8.3) 
C, 10.9 (7.4)
I, 40.3 (12.6) 
C, 35.6 (11.3)
Bucknall et al87 464 69.1 37 I, severe (stage 3) 
C, severe (stage 3)
Secondary care Yes Yes HADS HADS I, 8.5 (3.9) 
C, 8.3 (4.1)
I, 10 (4.5) 
C, 9.3 (4.6)
de Blok et al88 21 64.1 43 I, moderate (stage 2) 
C, severe (stage 3)
Tertiary care No No BDI N/A I, 12.6 (95% CI 7.5–17.7) 
C, 12.9 (95% CI 8.5–17.2)
N/A
de Godoy  
and de Godoy89
30 60.5 73 Severe (stage 3) Secondary care Yes Yes BDI BAI I, 13.7 (8.9)  
C, 14.9 (11.5)
I, 12.9 (6.9) 
C, 10.9 (9.8)
Donesky- 
Cuenco et al90
41 70 28 I, moderate (stage 2) 
C, severe (stage 3)
Primary care No No CeS-D STAI I, 9.5 (4.5) 
C, 12.6 (9.4)
I, 30.2 (8)  
C, 33.8 (9)
Effing et al91 142 63.4 59 I, moderate (stage 2) 
C, severe (stage 3)
Secondary care No No HADS HADS I, 4.4 (3.5)  
C, 4.6 (4)
I, 4.6 (3.3) 
C, 4.8 (4)
elçi et al92 78 58.9 85 Severe (stage 3) Tertiary care No No HADS HADS Not reported Not reported
emery et al93 79 66.6 47 Severe (stage 3) Primary care No No SCL-depression SCL-anxiety I, 59.2 (7.6)a 
I, 55.5 (5.3)b 
C, 60 (7.7)
I, 54.3 (7.2)a 
I, 54.0 (5.3)b 
C, 53.4 (4.5)
Gift et al94 26 68.5 31 Moderate (stage 2) Primary care No No N/A STAI N/A I, 45 (9) 
C, 37 (6)
Griffiths et al95 200 68.3 60 Severe (stage 3) Primary care and 
secondary care
No No HADS HADS I, 7.3 (3.2)  
C, 7.5 (4.3)
I, 8.6 (4.7) 
C, 8.9 (4.3)
Güell et al96 40 67 94 Severe (stage 3) Tertiary care No No SCL-90-R SCL-90-R I, 1.3 (0.8) 
C, 0.6 (0.6)
I, 1.0 (0.5) 
C, 0.6 (0.7)
Hospes et al97 39 62.2 60 Moderate (stage 2) Secondary care No No BDI N/A I, 8.4 (5.2)  
C, 9.1 (8.3)
N/A
Hynninen et al98 51 61 49 Moderate (stage 2) Secondary care Yes Yes BDI-II BAI I, 20.7 (8.6)  
C, 20.5 (9.7)
I, 17.5 (7.3) 
C, 17.5 (9.5)
Kapella et al99 23 63 83 I, moderate (stage 2)
C, moderate (stage 2)
Community Unknown Unknown POMS-D POMS-A I, 9.9 (10.3) 
C, 10.4 (8.2)
I, 9.4 (8.2) 
C, 8.6 (3.7)
Kayahan et al100 45 66 87 Moderate (stage 2) Tertiary care No No HAM-D HAM-A I, 5.43 (4.8) 
C, 7.18 (6.5)
I, 8.91 (6.9) 
C, 7.91 (6.6)
Kunik et al101 53 71.3 83 Severe (stage 3) Secondary care No No GDS BAI I, 11.5 (0.3) 
C, 7.7 (5.4)
I, 15.3 (9.2) 
C, 10 (6.8)
Kunik et al102 238 66.3 97 Severe (stage 3) Primary care Yes Yes BDI-II BAI I, 23.4 (12.5) 
C, 21.1 (12)
I, 22.67 (14.2) 
C, 23 (13.9)
Lamers et al103 187 71 60 Mild to moderate  
(stage 1 to 2)
Primary care Yes No BDI-II SCL I, 17.1 (6.5) 
C, 18.3 (7.2)
I, 20.6 (6.2) 
C, 20.4 (7.3)
Livermore et al104 41 73.4 44 Moderate (stage 2) Secondary care No No HADS HADS I, 3.9 (2.1) 
C, 4.1 (2.8)
I, 5.2 (2.9) 
C, 5.9 (2.7)
Lolak et al105 83 67.7 37 Severe (stage 3) Secondary care No No HADS HADS I, 6.6 (4) 
C, 4.9 (3)
T, 6 (4.3) 
C, 6.35 (3.8)
Lord et al106 28 67.4 Not  
stated
Severe (stage 3) Secondary care No No HADS HADS I, 5.7 (2.8) 
C, 5.8 (3.6)
I, 6.3 (3.1) 
C, 5.3 (2.6)
McGeoch et al107 159 71 59.5 Moderate (stage 2) Primary care No No HADS HADS I, 4.6 (3.7) 
C, 4.1 (2.9)
I, 6.2 (4.2) 
C, 5.3 (3.6)
Özdemir et al108 50 62.5 100 Moderate (stage 2) Tertiary care No No HADS HADS I, 6 (3) 
C, 7.0 (4.6)
I, 6.8 (3.2) 
C, 7.1 (4.9)
Paz-Díaz et al109 24 64.5 73 Severe (stage 3) Secondary care No No BDI STAI I, 14 (8) 
C, 18 (8)
I, 35 (26) 
C, 33 (25)
Ries et al114 119 62.6 73 Severe (stage 3) Primary care No No CeS-D N/A I, 14.0 (8.7) 
C, 15.3 (10)
N/A
Sassi-Dambron  
et al110
89 67.4 55 Moderate (stage 2) Secondary care No No CeS-D STAI I, 14.2 (10.2) 
C, 11.9 (7.6)
I, 33.8 (9.7) 
C, 34.1 (9.5)
Spencer et al111 59 66 46 Moderate (stage 2) Secondary care No No HADS HADS I, 4 (2) 
C, 5 (3)
I, 6 (3) 
C, 6 (3)
(Continued)International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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Table 1 Characteristics of the study populations
Reference Sample  
size
Mean 
age, years
Males 
(%)
COPD severity 
(GOLD stage)
Where  
recruited
Depressed  
at baseline
Anxious  
at baseline
Depression  
assessment
Anxiety 
assessment
Baseline mean (SD)  
depression score
Baseline mean (SD) 
anxiety score
Blumenthal  
et al86
158 50 44 Severe (stage 3) Secondary care No No BDI STAI I, 13.4 (8.3) 
C, 10.9 (7.4)
I, 40.3 (12.6) 
C, 35.6 (11.3)
Bucknall et al87 464 69.1 37 I, severe (stage 3) 
C, severe (stage 3)
Secondary care Yes Yes HADS HADS I, 8.5 (3.9) 
C, 8.3 (4.1)
I, 10 (4.5) 
C, 9.3 (4.6)
de Blok et al88 21 64.1 43 I, moderate (stage 2) 
C, severe (stage 3)
Tertiary care No No BDI N/A I, 12.6 (95% CI 7.5–17.7) 
C, 12.9 (95% CI 8.5–17.2)
N/A
de Godoy  
and de Godoy89
30 60.5 73 Severe (stage 3) Secondary care Yes Yes BDI BAI I, 13.7 (8.9)  
C, 14.9 (11.5)
I, 12.9 (6.9) 
C, 10.9 (9.8)
Donesky- 
Cuenco et al90
41 70 28 I, moderate (stage 2) 
C, severe (stage 3)
Primary care No No CeS-D STAI I, 9.5 (4.5) 
C, 12.6 (9.4)
I, 30.2 (8)  
C, 33.8 (9)
Effing et al91 142 63.4 59 I, moderate (stage 2) 
C, severe (stage 3)
Secondary care No No HADS HADS I, 4.4 (3.5)  
C, 4.6 (4)
I, 4.6 (3.3) 
C, 4.8 (4)
elçi et al92 78 58.9 85 Severe (stage 3) Tertiary care No No HADS HADS Not reported Not reported
emery et al93 79 66.6 47 Severe (stage 3) Primary care No No SCL-depression SCL-anxiety I, 59.2 (7.6)a 
I, 55.5 (5.3)b 
C, 60 (7.7)
I, 54.3 (7.2)a 
I, 54.0 (5.3)b 
C, 53.4 (4.5)
Gift et al94 26 68.5 31 Moderate (stage 2) Primary care No No N/A STAI N/A I, 45 (9) 
C, 37 (6)
Griffiths et al95 200 68.3 60 Severe (stage 3) Primary care and 
secondary care
No No HADS HADS I, 7.3 (3.2)  
C, 7.5 (4.3)
I, 8.6 (4.7) 
C, 8.9 (4.3)
Güell et al96 40 67 94 Severe (stage 3) Tertiary care No No SCL-90-R SCL-90-R I, 1.3 (0.8) 
C, 0.6 (0.6)
I, 1.0 (0.5) 
C, 0.6 (0.7)
Hospes et al97 39 62.2 60 Moderate (stage 2) Secondary care No No BDI N/A I, 8.4 (5.2)  
C, 9.1 (8.3)
N/A
Hynninen et al98 51 61 49 Moderate (stage 2) Secondary care Yes Yes BDI-II BAI I, 20.7 (8.6)  
C, 20.5 (9.7)
I, 17.5 (7.3) 
C, 17.5 (9.5)
Kapella et al99 23 63 83 I, moderate (stage 2)
C, moderate (stage 2)
Community Unknown Unknown POMS-D POMS-A I, 9.9 (10.3) 
C, 10.4 (8.2)
I, 9.4 (8.2) 
C, 8.6 (3.7)
Kayahan et al100 45 66 87 Moderate (stage 2) Tertiary care No No HAM-D HAM-A I, 5.43 (4.8) 
C, 7.18 (6.5)
I, 8.91 (6.9) 
C, 7.91 (6.6)
Kunik et al101 53 71.3 83 Severe (stage 3) Secondary care No No GDS BAI I, 11.5 (0.3) 
C, 7.7 (5.4)
I, 15.3 (9.2) 
C, 10 (6.8)
Kunik et al102 238 66.3 97 Severe (stage 3) Primary care Yes Yes BDI-II BAI I, 23.4 (12.5) 
C, 21.1 (12)
I, 22.67 (14.2) 
C, 23 (13.9)
Lamers et al103 187 71 60 Mild to moderate  
(stage 1 to 2)
Primary care Yes No BDI-II SCL I, 17.1 (6.5) 
C, 18.3 (7.2)
I, 20.6 (6.2) 
C, 20.4 (7.3)
Livermore et al104 41 73.4 44 Moderate (stage 2) Secondary care No No HADS HADS I, 3.9 (2.1) 
C, 4.1 (2.8)
I, 5.2 (2.9) 
C, 5.9 (2.7)
Lolak et al105 83 67.7 37 Severe (stage 3) Secondary care No No HADS HADS I, 6.6 (4) 
C, 4.9 (3)
T, 6 (4.3) 
C, 6.35 (3.8)
Lord et al106 28 67.4 Not  
stated
Severe (stage 3) Secondary care No No HADS HADS I, 5.7 (2.8) 
C, 5.8 (3.6)
I, 6.3 (3.1) 
C, 5.3 (2.6)
McGeoch et al107 159 71 59.5 Moderate (stage 2) Primary care No No HADS HADS I, 4.6 (3.7) 
C, 4.1 (2.9)
I, 6.2 (4.2) 
C, 5.3 (3.6)
Özdemir et al108 50 62.5 100 Moderate (stage 2) Tertiary care No No HADS HADS I, 6 (3) 
C, 7.0 (4.6)
I, 6.8 (3.2) 
C, 7.1 (4.9)
Paz-Díaz et al109 24 64.5 73 Severe (stage 3) Secondary care No No BDI STAI I, 14 (8) 
C, 18 (8)
I, 35 (26) 
C, 33 (25)
Ries et al114 119 62.6 73 Severe (stage 3) Primary care No No CeS-D N/A I, 14.0 (8.7) 
C, 15.3 (10)
N/A
Sassi-Dambron  
et al110
89 67.4 55 Moderate (stage 2) Secondary care No No CeS-D STAI I, 14.2 (10.2) 
C, 11.9 (7.6)
I, 33.8 (9.7) 
C, 34.1 (9.5)
Spencer et al111 59 66 46 Moderate (stage 2) Secondary care No No HADS HADS I, 4 (2) 
C, 5 (3)
I, 6 (3) 
C, 6 (3)
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Table 1 (Continued)
Reference Sample  
size
Mean 
age, years
Males 
(%)
COPD severity 
(GOLD stage)
Where  
recruited
Depressed  
at baseline
Anxious  
at baseline
Depression  
assessment
Anxiety 
assessment
Baseline mean (SD)  
depression score
Baseline mean (SD) 
anxiety score
Taylor et al112 116 69.5 46 Moderate (stage 2) Primary care No No HADS HADS I, 5.4 
C, 4.8
I, 6.1 
C, 6.7
Yeh et al113 10 65.5 60 Moderate (stage 2) Secondary care No No CeS-D N/A I, 14 (11–46) 
C, 12 (2–17)  
(median, range)
N/A
Alexopoulos  
et al68
138 68.5 Not  
stated
Severe (stage 3) Tertiary care Yes N/A HAM-D N/A I, 24.72 (3.86) 
C, 24.80 (3.46)
N/A
Gurgun et al65 46 64.7 95.6 Severe (stage 3) Tertiary care No No HADS HADS I, 8.4 (3.1)a 
I, 6.8 (3.6)b 
C, 8.8 (4.5)
I, 9.1 (5.6)a 
I, 6.8 (4.9)b 
C, 8.8 (4.5)
Jiang et al69 100 64.9 
5
69.75 Control: moderate (stage 2)  
63.8%; severe (stage 3) 36.2%  
Intervention: moderate (stage 2)  
59.2%; severe (stage 3) 40.8%
Tertiary care No No HADS STAI I, 7.16 (3.02) 
C, 7.08 (2.92)
Trait anxiety: 
I, 42.91 (6.78) 
C, 42.46 (7.04)
wadell et al66 48 55.8 56 Severe (stage 3) Tertiary care No No HADS HADS I, 5.1 (3.3) 
C, 4.2 (2.9)
I, 5.8 (3.5) 
C, 4.5 (2.8)
walters et al67 182 67 52.5 Moderate (stage 2) Primary care No No HADS, CeS-D HADS HADS: I, 4.6 (3.1) 
C, 5.1 (3.6)
CeS-D: I, 4.6 (3.1) 
C, 5.1 (3.6)
I, 6.7 (4.1) 
C, 7 (4.1)
Notes: aComparison 1, exercise, education, and stress management. bComparison 2, education and stress management.
Abbreviations: BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CES-D, Centre for Epidemiologic Studies Depression Scale; C, Control group; CI, confidence 
interval; COPD, chronic obstructive pulmonary disease; GDS, Geriatric Depression Scale; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HADS, Hospital 
Anxiety and Depression Scale; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; I, intervention group; N/A, not applicable; POMS-A, 
Profile of Mood States Anxiety scale; POMS-D, Profile of Mood States Depression scale; SCL, Symptom Checklist; SCL-90-R, Symptom Checklist-90-Revised; SD, standard 
deviation; STAI, State Trait Anxiety Inventory.
with an exercise component, relaxation techniques, and 
self-management education. This meta-analysis included 
29 randomized controlled trials and 2,063 participants, 
and demonstrated that the pooled effects of psychological 
and/or lifestyle interventions led to small but significant 
reductions in symptoms of depression (standardized mean 
difference [SMD] 0.28, 95% CI -0.41, -0.14) and anxiety 
(SMD -0.23, 95% CI -0.38, -0.09). When grouped accord-
ing to intervention components, the only intervention 
associated with significant improvements in symptoms of 
depression (SMD -0.47, 95% CI -0.66, -0.28) and anxiety 
(SMD -0.45, 95% CI -0.71, -0.18) was multicomponent 
pulmonary rehabilitation. Cognitive and behavioral treat-
ment approaches and relaxation techniques were associated 
with small but not significant reductions in depression and 
anxiety. Self-management interventions that included disease 
education did not have an effect on depression or anxiety 
symptoms.
When the analysis was restricted to the five trials that 
included both psychological and exercise components, 
the effect size increased to 0.64 for depression and to 
0.59 for anxiety, suggesting that complex interventions 
containing a combination of psychological techniques and 
exercise training have the greatest effects on depression 
and anxiety.62
This meta-analysis observed a great variability in the 
methods used to assess depression and anxiety across the 
studies included in the meta-analysis; some of the studies 
included patients with a diagnosis of depression and anxiety, 
while others measured symptoms of depression and anxiety 
(some of which did not report above threshold levels of depres-
sion). Coventry et al showed that the effectiveness of psycho-
logical and/or lifestyle interventions for reducing symptoms 
of depression and anxiety is equivalent across studies with 
confirmed depressed or above threshold samples (SMD -0.29   
and -0.21 for depression and anxiety, respectively) and 
studies with unknown levels of depression and anxiety at 
baseline (SMD -0.24 and -0.27 for depression and anxiety, 
respectively).62 Better reporting of severity of depression at 
baseline in clinical trials will aid more informed assessment 
of the impact of symptom severity on treatment outcomes.
Updated systematic review
In recognition of the expanding evidence base and the clinical 
importance of this area, we updated the systematic review 
completed by Coventry et al in 2013.62International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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Table 1 (Continued)
Reference Sample  
size
Mean 
age, years
Males 
(%)
COPD severity 
(GOLD stage)
Where  
recruited
Depressed  
at baseline
Anxious  
at baseline
Depression  
assessment
Anxiety 
assessment
Baseline mean (SD)  
depression score
Baseline mean (SD) 
anxiety score
Taylor et al112 116 69.5 46 Moderate (stage 2) Primary care No No HADS HADS I, 5.4 
C, 4.8
I, 6.1 
C, 6.7
Yeh et al113 10 65.5 60 Moderate (stage 2) Secondary care No No CeS-D N/A I, 14 (11–46) 
C, 12 (2–17)  
(median, range)
N/A
Alexopoulos  
et al68
138 68.5 Not  
stated
Severe (stage 3) Tertiary care Yes N/A HAM-D N/A I, 24.72 (3.86) 
C, 24.80 (3.46)
N/A
Gurgun et al65 46 64.7 95.6 Severe (stage 3) Tertiary care No No HADS HADS I, 8.4 (3.1)a 
I, 6.8 (3.6)b 
C, 8.8 (4.5)
I, 9.1 (5.6)a 
I, 6.8 (4.9)b 
C, 8.8 (4.5)
Jiang et al69 100 64.9 
5
69.75 Control: moderate (stage 2)  
63.8%; severe (stage 3) 36.2%  
Intervention: moderate (stage 2)  
59.2%; severe (stage 3) 40.8%
Tertiary care No No HADS STAI I, 7.16 (3.02) 
C, 7.08 (2.92)
Trait anxiety: 
I, 42.91 (6.78) 
C, 42.46 (7.04)
wadell et al66 48 55.8 56 Severe (stage 3) Tertiary care No No HADS HADS I, 5.1 (3.3) 
C, 4.2 (2.9)
I, 5.8 (3.5) 
C, 4.5 (2.8)
walters et al67 182 67 52.5 Moderate (stage 2) Primary care No No HADS, CeS-D HADS HADS: I, 4.6 (3.1) 
C, 5.1 (3.6)
CeS-D: I, 4.6 (3.1) 
C, 5.1 (3.6)
I, 6.7 (4.1) 
C, 7 (4.1)
Notes: aComparison 1, exercise, education, and stress management. bComparison 2, education and stress management.
Abbreviations: BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CES-D, Centre for Epidemiologic Studies Depression Scale; C, Control group; CI, confidence 
interval; COPD, chronic obstructive pulmonary disease; GDS, Geriatric Depression Scale; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HADS, Hospital 
Anxiety and Depression Scale; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; I, intervention group; N/A, not applicable; POMS-A, 
Profile of Mood States Anxiety scale; POMS-D, Profile of Mood States Depression scale; SCL, Symptom Checklist; SCL-90-R, Symptom Checklist-90-Revised; SD, standard 
deviation; STAI, State Trait Anxiety Inventory.
Methods
The methods used to search, select, extract, and analyze data 
resembled that reported in the original systematic review.62 
To avoid repetition, we will only briefly present some key 
methodological aspects of this updated systematic review.
Data sources and search strategy
All searches were initially carried out from inception to 
April 201262 and were updated in April 2014. The follow-
ing electronic databases were searched: Medline, Embase, 
PsycINFO, Cinahl, Web of Science, and Scopus. The above 
searches were complemented by hand searches of the refer-
ence lists of the included studies.
eligibility criteria
Studies had to fulfill the following criteria to be included in 
the review (see Coventry et al62 for more details):
•	 Study design – cluster or individual randomized con-
trolled trials
•	 Population – individuals with COPD confirmed by post-
bronchodilator spirometry of forced expiratory volume in 
1 second/forced vital capacity ratio of 70%, and a forced 
expiratory volume in 1 second of 80%
•	 Intervention – single or multiple component interventions 
that include psychological and/or lifestyle components
•	 Comparators – any control (eg, waiting list, usual care, 
attention or active control)
•	 Outcomes – standardized measure of depression and/or 
anxiety.
Study selection and data extraction
The titles/abstracts and the full texts of potentially relevant 
studies were screened by four reviewers independently. Data 
were extracted using a standardized data extraction form. 
Extracted data included characteristics of patients, interven-
tions, outcomes, and quality appraisal of the studies. Study 
authors were contracted to retrieve data not available in pub-
lished reports. Any disagreements during the process of study 
selection and data extraction were resolved by consensus in 
group meetings with all review authors.
Data analysis
Meta-analyses using random effects models were undertaken 
to assess the effectiveness of different types of complex 
interventions on reducing symptoms of depression and 
anxiety in those with COPD. Effect sizes were expressed International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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Table 2 Characteristics of the interventions
Reference Intervention Control group Lifestyle  
components
Psychological  
components
Sessions (n) Session length 
(minutes)
Delivered by Delivery method Follow-up
Alexopoulos  
et al68
Problem-solving techniques Usual care education Problem-solving techniques 9 30 (for discharge  
session)
Social workers Not reported (first session  
was at discharge and remainder  
in their own homes)
28 weeks
Blumenthal  
et al86
Telephone-based  
coping skills training
Usual medical care including  
clinic visits with pulmonologists  
and regular contact with nurse  
coordinators
General education  
Relapse prevention
Problem-solving techniques 
CBT relaxation
12 30 Clinical psychologists,  
social workers
Individual, face-to-face,  
and remote
12 weeks
Bucknall et al87  Supported self-management Usual medical care from GP  
and hospital based specialists  
(including out of hours care)
General education,  
skills training
Miscellaneous 
(empowerment and 
increased self-efficacy)
22 40 Respiratory nurses Individual, face-to-face 52 weeks
de Blok et al88 PR plus physical activity  
counseling
Regular PR containing exercise  
training, dietary intervention  
and educational modules
General education  
exercise skills training,  
behavior therapy
Biofeedback miscellaneous 
(physical activity counselling, 
motivational interviewing)
4 30 Physical therapists Group and individual,  
face-to-face
9 weeks
de Godoy  
and de Godoy89
CBT, physiotherapy,  
exercise and education
Physiotherapy, exercise,  
and education
General education  
exercise 
Skills training
CBT relaxation  
Miscellaneous (logotherapy)
24 exercise sessions  
24 physiotherapy sessions 
12 psychotherapy sessions
Not reported Respiratory physicians Group, face-to-face 12 weeks
Donesky- 
Cuenco  
et al 200990
Yoga training Usual care (also received  
educational pamphlet, offered yoga  
at the end as waiting list control)
exercise
Skills training
Miscellaneous (relaxation) 24 60 expert yoga instructors Group, face-to-face 12 weeks
Effing et al91 Psychotherapeutic exercise;  
self- management education
Self-management education General education
Skills training
exercise
Problem-solving techniques Four education sessions 
First phase: 72 exercise sessions  
Second phase: 40 voluntary  
exercise sessions
120 education  
sessions
Respiratory nurse  
and physiotherapist
Group, face-to-face,  
and remote
28 weeks
elçi et al92 PR Standard medical care  
(including instructions on use  
of respiratory medicines)
General education  
exercise
Skills training
Miscellaneous 
(psychological counseling)
24 90 Nurse Individual, face-to-face,  
and remote
4 weeks
emery et al93 Treatment
a.    exercise, education  
and stress management
Treatment
b.    education and stress  
management
waiting list control General education  
Group discussion  
exercise
CBT relaxation  
Miscellaneous  
(stress management)
37 exercise classes 
16 lectures 
10 stress management sessions
240  
(all modules)
Respiratory specialists  
and clinical psychologist
Group, face-to-face 10 weeks
Gift et al94  Progressive muscle relaxation  
with prerecorded tapes
Participants instructed to  
sit quietly for 20 minutes
N/A Relaxation (Bernstein and 
Borkovec method)
4 20 Primary care practitioners Individual, face-to-face 4 weeks
Griffiths et al95 Multidisciplinary PR Standard medical management General education  
exercise
Skills training
Relaxation miscellaneous 
(stress management to 
promote mastery and 
control over illness)
18 120 Occupational therapist,  
physiotherapist, dietetic staff,  
specialist respiratory nurse, and  
a smoking cessation counselor
Group, face-to-face 6 weeks
Güell et al96 PR including breathing  
training and exercise
Usual care General education  
exercise
Skills training
Relaxation Phase 1, 16 sessions 
Phase 2, 40 sessions
30 Not reported Group, face-to-face 16 weeks
Gurgun et al65 PR with exercise, education  
and nutritional supplementation
Usual care exercise, education Relaxation 16 60–80 Not stated Not stated 8 weeks
Hospes et al97 Pedometer-based exercise 
counseling program
Usual care exercise Biofeedback problem- 
solving techniques  
exercise counseling  
Motivational interviewing
5 30 Trained exercise counselor Individual, face-to-face 12 weeks
Hynninen et al98 CBT enhanced standard care  
for COPD
N/A CBT 7 60 Masters level psychology  
student
Group, face-to-face 4 weeks
Jiang et al69 Uncertainty management  
with CBT
Usual care Skills training CBT, relaxation 4 35 Intervention nurses Telephone 40 weeks
Kapella et al99 CBT COPD education N/A CBT 6 Not reported Nurse behavioral sleep  
medicine specialist
Group, face-to-face 6 weeks
Kayahan et al100 PR Usual care General education  
exercise
Skills training
Relaxation 24 150 Not reported Individual and group,  
face-to-face
8 weeks
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Table 2 Characteristics of the interventions
Reference Intervention Control group Lifestyle  
components
Psychological  
components
Sessions (n) Session length 
(minutes)
Delivered by Delivery method Follow-up
Alexopoulos  
et al68
Problem-solving techniques Usual care education Problem-solving techniques 9 30 (for discharge  
session)
Social workers Not reported (first session  
was at discharge and remainder  
in their own homes)
28 weeks
Blumenthal  
et al86
Telephone-based  
coping skills training
Usual medical care including  
clinic visits with pulmonologists  
and regular contact with nurse  
coordinators
General education  
Relapse prevention
Problem-solving techniques 
CBT relaxation
12 30 Clinical psychologists,  
social workers
Individual, face-to-face,  
and remote
12 weeks
Bucknall et al87  Supported self-management Usual medical care from GP  
and hospital based specialists  
(including out of hours care)
General education,  
skills training
Miscellaneous 
(empowerment and 
increased self-efficacy)
22 40 Respiratory nurses Individual, face-to-face 52 weeks
de Blok et al88 PR plus physical activity  
counseling
Regular PR containing exercise  
training, dietary intervention  
and educational modules
General education  
exercise skills training,  
behavior therapy
Biofeedback miscellaneous 
(physical activity counselling, 
motivational interviewing)
4 30 Physical therapists Group and individual,  
face-to-face
9 weeks
de Godoy  
and de Godoy89
CBT, physiotherapy,  
exercise and education
Physiotherapy, exercise,  
and education
General education  
exercise 
Skills training
CBT relaxation  
Miscellaneous (logotherapy)
24 exercise sessions  
24 physiotherapy sessions 
12 psychotherapy sessions
Not reported Respiratory physicians Group, face-to-face 12 weeks
Donesky- 
Cuenco  
et al 200990
Yoga training Usual care (also received  
educational pamphlet, offered yoga  
at the end as waiting list control)
exercise
Skills training
Miscellaneous (relaxation) 24 60 expert yoga instructors Group, face-to-face 12 weeks
Effing et al91 Psychotherapeutic exercise;  
self- management education
Self-management education General education
Skills training
exercise
Problem-solving techniques Four education sessions 
First phase: 72 exercise sessions  
Second phase: 40 voluntary  
exercise sessions
120 education  
sessions
Respiratory nurse  
and physiotherapist
Group, face-to-face,  
and remote
28 weeks
elçi et al92 PR Standard medical care  
(including instructions on use  
of respiratory medicines)
General education  
exercise
Skills training
Miscellaneous 
(psychological counseling)
24 90 Nurse Individual, face-to-face,  
and remote
4 weeks
emery et al93 Treatment
a.    exercise, education  
and stress management
Treatment
b.    education and stress  
management
waiting list control General education  
Group discussion  
exercise
CBT relaxation  
Miscellaneous  
(stress management)
37 exercise classes 
16 lectures 
10 stress management sessions
240  
(all modules)
Respiratory specialists  
and clinical psychologist
Group, face-to-face 10 weeks
Gift et al94  Progressive muscle relaxation  
with prerecorded tapes
Participants instructed to  
sit quietly for 20 minutes
N/A Relaxation (Bernstein and 
Borkovec method)
4 20 Primary care practitioners Individual, face-to-face 4 weeks
Griffiths et al95 Multidisciplinary PR Standard medical management General education  
exercise
Skills training
Relaxation miscellaneous 
(stress management to 
promote mastery and 
control over illness)
18 120 Occupational therapist,  
physiotherapist, dietetic staff,  
specialist respiratory nurse, and  
a smoking cessation counselor
Group, face-to-face 6 weeks
Güell et al96 PR including breathing  
training and exercise
Usual care General education  
exercise
Skills training
Relaxation Phase 1, 16 sessions 
Phase 2, 40 sessions
30 Not reported Group, face-to-face 16 weeks
Gurgun et al65 PR with exercise, education  
and nutritional supplementation
Usual care exercise, education Relaxation 16 60–80 Not stated Not stated 8 weeks
Hospes et al97 Pedometer-based exercise 
counseling program
Usual care exercise Biofeedback problem- 
solving techniques  
exercise counseling  
Motivational interviewing
5 30 Trained exercise counselor Individual, face-to-face 12 weeks
Hynninen et al98 CBT enhanced standard care  
for COPD
N/A CBT 7 60 Masters level psychology  
student
Group, face-to-face 4 weeks
Jiang et al69 Uncertainty management  
with CBT
Usual care Skills training CBT, relaxation 4 35 Intervention nurses Telephone 40 weeks
Kapella et al99 CBT COPD education N/A CBT 6 Not reported Nurse behavioral sleep  
medicine specialist
Group, face-to-face 6 weeks
Kayahan et al100 PR Usual care General education  
exercise
Skills training
Relaxation 24 150 Not reported Individual and group,  
face-to-face
8 weeks
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Table 2 (Continued)
Reference Intervention Control group Lifestyle  
components
Psychological 
components
Sessions (n) Session length 
(minutes)
Delivered by Delivery method Follow-up
Kunik et al101 CBT COPD education N/A CBT 1 (+6 phone calls) 120 Board-certified  
gero-psychiatrist
Group, face-to-face  
and individual, remote
6 weeks
Kunik et al102 CBT group treatment  
intervention
COPD education N/A CBT 8 60 Psychology interns and  
postdoctoral fellows
Group, face-to-face 4 weeks
Lamers et al103 Minimal psychological  
intervention
Usual care Skills training Problem-solving  
techniques CBT
Average of 4 contacts 60 Primary care nurses Individual, face-to-face 12 week
Livermore et al104 CBT Routine care (including PR) N/A CBT 4 60 Clinical psychologist Individual, face-to-face 6 weeks
Lolak et al105 Progressive muscle  
relaxation and PR
exercise training General education  
exercise
Skills training
Relaxation (Bernstein  
and Borkovec method)
12 60 Multidisciplinary PR team Group, face-to-face 8 weeks
Lord et al106 Singing teaching Usual care Skills training Relaxation 12 60 Singing teacher Group, face-to-face 7 weeks
McGeoch et al107 Usual care and education  
on the use of a written  
self-management plan
Usual GP care General education  
Skills training
N/A 1 60 Practice nurse or respiratory  
educator in association  
with GP
Individual, face-to-face 24 weeks
Özdemir et al108 water-based PR Usual care exercise N/A 12 35 Physiotherapist  
and chest physician
Group, face-to-face 4 weeks
Paz-Díaz et al109 exercise rehabilitation  
program
Usual care exercise
Skills training
Miscellaneous (relaxation 
techniques)
24 85 Not reported Group, face-to-face 8 weeks
Ries114 Pulmonary rehabilitation education (videotapes, lectures,  
and discussions but no individual  
instruction or exercise training)
General education  
exercise
Skills training
Relaxation miscellaneous 
(psychological support)
12 240 Not reported Group, face-to-face 8 weeks
Sassi-Dambron  
et al110
Dyspnea self-management  
training
General health education General education  
Group discussion  
Skills training
Relaxation (progressive  
muscle relaxation) 
Miscellaneous (self-talk  
and panic control)
6 Not reported Graduate student  
in psychology and  
a clinical nurse
Group, face-to-face 6 weeks
Spencer et al111 Supervised outpatient-based  
exercise plus unsupervised  
home exercise
Unsupervised exercise exercise N/A 52 50 Physiotherapist Group, face-to-face 12 weeks
Taylor et al112 Disease-specific self- 
management program
Usual care Skills training Miscellaneous (self-
management using social 
cognitive self-efficacy theory)
7 150 Lay trainer and  
respiratory physician
Group, face-to-face 8 weeks
wadell et al66 PR Usual care exercise, education Miscellaneous (managing 
emotions and stress)
24 210 COPD nurse Face-to-face 8 weeks
walters et al67 Health mentoring using  
negotiated goal setting
Usual care education,  
skills training
CBT, problem-solving 
techniques
16 30 Community health  
nurses
Telephone 24 weeks
Yeh et al113 Tai Chi classes Usual care exercise Relaxation miscellaneous 
(meditation and mindfulness)
24 60 Tai Chi instructors Group, face-to-face 12 weeks
Abbreviations: CBT, cognitive and behavioral therapy; COPD, chronic obstructive pulmonary disease; GP, general practitioner; N/A, not applicable; PR, pulmonary 
rehabilitation.
as the SMD; an SMD of 0.56–1.2 is large, SMD 0.33–0.55 
is moderate, and SMD of ,0.32 is small.63 Heterogeneity 
was evaluated using the I2, which provides a quantitative 
measure of the degree of between-study differences caused 
by factors other than sampling error; higher I2 rates indicate 
higher heterogeneity.64
Results
The updated searches yielded 736 citations excluding 
  duplicates. Of these, 714 citations were excluded at the title 
and abstract screening stage. The full texts for 22 citations 
were retrieved and checked against the eligibility criteria of 
the review. Following full-text screening, we identified five 
additional studies (providing six relevant comparisons) as 
eligible for inclusion in the review.
Characteristics of included studies
A total of 34 studies that provided 36 relevant comparisons 
(n=2,577) were included in the updated meta-analysis. The 
COPD patients had a median age of 66 years with an equal 
sex distribution. The severity of COPD ranged from moderate 
to severe across the majority of the studies (see Table 1 for 
patient characteristics).
The majority of studies (80%) evaluated complex inter-
ventions that included both psychological and lifestyle com-
ponents, while six included only psychological components, International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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Table 2 (Continued)
Reference Intervention Control group Lifestyle  
components
Psychological 
components
Sessions (n) Session length 
(minutes)
Delivered by Delivery method Follow-up
Kunik et al101 CBT COPD education N/A CBT 1 (+6 phone calls) 120 Board-certified  
gero-psychiatrist
Group, face-to-face  
and individual, remote
6 weeks
Kunik et al102 CBT group treatment  
intervention
COPD education N/A CBT 8 60 Psychology interns and  
postdoctoral fellows
Group, face-to-face 4 weeks
Lamers et al103 Minimal psychological  
intervention
Usual care Skills training Problem-solving  
techniques CBT
Average of 4 contacts 60 Primary care nurses Individual, face-to-face 12 week
Livermore et al104 CBT Routine care (including PR) N/A CBT 4 60 Clinical psychologist Individual, face-to-face 6 weeks
Lolak et al105 Progressive muscle  
relaxation and PR
exercise training General education  
exercise
Skills training
Relaxation (Bernstein  
and Borkovec method)
12 60 Multidisciplinary PR team Group, face-to-face 8 weeks
Lord et al106 Singing teaching Usual care Skills training Relaxation 12 60 Singing teacher Group, face-to-face 7 weeks
McGeoch et al107 Usual care and education  
on the use of a written  
self-management plan
Usual GP care General education  
Skills training
N/A 1 60 Practice nurse or respiratory  
educator in association  
with GP
Individual, face-to-face 24 weeks
Özdemir et al108 water-based PR Usual care exercise N/A 12 35 Physiotherapist  
and chest physician
Group, face-to-face 4 weeks
Paz-Díaz et al109 exercise rehabilitation  
program
Usual care exercise
Skills training
Miscellaneous (relaxation 
techniques)
24 85 Not reported Group, face-to-face 8 weeks
Ries114 Pulmonary rehabilitation education (videotapes, lectures,  
and discussions but no individual  
instruction or exercise training)
General education  
exercise
Skills training
Relaxation miscellaneous 
(psychological support)
12 240 Not reported Group, face-to-face 8 weeks
Sassi-Dambron  
et al110
Dyspnea self-management  
training
General health education General education  
Group discussion  
Skills training
Relaxation (progressive  
muscle relaxation) 
Miscellaneous (self-talk  
and panic control)
6 Not reported Graduate student  
in psychology and  
a clinical nurse
Group, face-to-face 6 weeks
Spencer et al111 Supervised outpatient-based  
exercise plus unsupervised  
home exercise
Unsupervised exercise exercise N/A 52 50 Physiotherapist Group, face-to-face 12 weeks
Taylor et al112 Disease-specific self- 
management program
Usual care Skills training Miscellaneous (self-
management using social 
cognitive self-efficacy theory)
7 150 Lay trainer and  
respiratory physician
Group, face-to-face 8 weeks
wadell et al66 PR Usual care exercise, education Miscellaneous (managing 
emotions and stress)
24 210 COPD nurse Face-to-face 8 weeks
walters et al67 Health mentoring using  
negotiated goal setting
Usual care education,  
skills training
CBT, problem-solving 
techniques
16 30 Community health  
nurses
Telephone 24 weeks
Yeh et al113 Tai Chi classes Usual care exercise Relaxation miscellaneous 
(meditation and mindfulness)
24 60 Tai Chi instructors Group, face-to-face 12 weeks
Abbreviations: CBT, cognitive and behavioral therapy; COPD, chronic obstructive pulmonary disease; GP, general practitioner; N/A, not applicable; PR, pulmonary 
rehabilitation.
and four lifestyle interventions alone. Among the five trials 
identified from the new searches, two studies (including 
three comparisons) comprised multicomponent exer-
cise interventions65,66 and three studies comprised CBT 
interventions.67–69 None of the new trials evaluated relaxation 
techniques or self-management interventions (see Table 2 for 
intervention characteristics).
effects of different types of complex 
interventions on depression and anxiety
Thirty-four trials reported data on depression and 30   trials 
reported data on anxiety. As with the results of the   original 
review,62 the pooled effects of the interventions indicated small 
but significant improvements in depression (SMD -0.30, 95% 
CI -0.41, -0.19) and in anxiety (SMD -0.31, 95% CI -0.49, 
-0.10). Subgroup analysis showed that CBT interventions 
were associated with small and significant improvements in 
depression. The results for the subgroup of multicomponent 
exercise training interventions were unchanged; multicompo-
nent exercise training interventions were associated with the 
largest treatment effects in favor of a reduction in depression 
and anxiety (forest plot, Figures 1 and 2).
Implications for practice and research
Multicomponent exercise training with or without psycho-
logical support is associated with the greatest improvements International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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Reference Forest plot
−0.01 (−0.37, 0.34)
−0.54 (−1.10, 0.02)
0.10 (−0.82, 1.03)
0.08 (−0.49, 0.65)
−0.03 (−0.38, 0.33)
−0.29 (−0.64, 0.06)
−0.63 (−1.25, 0.00) −
−0.49 (−0.86, −0.13)
−0.42 (−0.82, −0.01)
−0.28 (−0.60, 0.03)
−0.26 (−0.40, −0.12)
−0.00 (−0.29, 0.28)
−0.28 (−0.85, 0.29)
0.07 (−0.24, 0.39)
−0.18 (−0.63, 0.27)
0.17 (−0.26, 0.61)
−0.00 (−0.17, 0.16)
0.09 (−0.89, 1.07)
−0.80 (−1.54, −0.05)
−0.21 (−0.55, 0.14)
−1.00 (−1.47, −0.53)
−0.49 (−1.05, 0.07)
−0.79 (−1.09, −0.49)
−0.18 (−0.85, 0.48)
−0.03 (−0.70, 0.63)
−0.46 (−1.05, 0.14)
−0.21 (−0.83, 0.41)
−0.68 (−1.25, −0.11)
−1.17 (−2.05, −0.29)
−0.11 (−0.48, 0.27)
−0.49 (−1.06, 0.09)
−0.19 (−1.05, 0.67)
−0.81 (−1.70, 0.08)
−0.65 (−1.28, −0.01)
−0.48 (−0.65, −0.31)
−0.25 (−0.98, 0.49)  
−0.34 (−1.09, 0.40)
0.45 (−0.81, 1.71)
−0.18 (−0.67, 0.30)
SMD (95% CI)
%
weight
CBT
Blumenthal96
Hynninen98
Kapella99
Kunik101
Kunik102
Lamers103
Livermore104
Alexopoulos68
Jang69
Walters67
Subtotal (l2=9.7%, P=0.353)
Self-management education
Bucknall87
Emery93,b
McGeoch107
Sassi-Dambron110
Taylor112
Subtotal (l2=0.0%, P=0.668)
Multi-component exercise training
de Blok88
de Godoy89
Effing91
Elçi92
Emery93,a
Griffiths95
Güell96
Hospes97
Kayahan100
Lolak105
Özdemir108
Paz-Díaz109
Ries114
Spencer111
Gurgun65,c
Gurgun65,d
Wadell66
Subtotal (l2=34.4%, P=0.081)
Relaxation
Donesky-Cuenco90
Lord94
Yeh113
Subtotal (l=0.0%, P=0.552)
−2 −1.5 −1 −0.5 0 0.5 1 1.5 2
Intervention Control
13.49
5.94
2.26
5.72
13.68
13.93
4.77
12.75
10.79
16.67
100.00
34.72
8.68
27.92
14.01
14.67
100.00
2.60
4.06
10.66
7.67
6.14
11.81
4.86
4.87
5.63
5.34
6.02
3.11
9.81
5.97
3.24
3.04
5.16
100.00
43.64
41.65
14.71
100.00
Note: Weights are from random effects analysis
Figure 1 effects of subgroups of complex interventions on self-reported depression at post-treatment.
Note: Random-effects model was used.  aIndependent comparison 1, exercise, education, and stress management;  bindependent comparison 2, education and stress 
management; cindependent comparison 1, pulmonary rehabilitation and nutritional support; dindependent comparison 2, pulmonary rehabilitation.
Abbreviations: CBT, cognitive and behavioral therapy; CI, confidence interval; SMD, standardized mean difference.
in symptoms of depression and anxiety in COPD compared 
with other nonpharmacological approaches. Components 
of pulmonary rehabilitation vary, but typically include pre-
scribed supervised exercise training and self-management 
advice as well as multidisciplinary education about COPD 
and nutrition for a minimum of 6 weeks. Psychological and 
behavioral interventions may also be provided in the context 
of self-management advice, with an emphasis on   promoting 
adaptive behaviors such as self-efficacy.51 However, psy-
chological interventions are rarely provided alongside or 
integrated within pulmonary rehabilitation.70 Future research 
could address whether mental health professionals, in collabo-
ration with multidisciplinary pulmonary rehabilitation teams, 
could play important roles in the delivery of psychological International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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Reference Forest plot
CBT
Blumenthal86
Hynninen98
Kapella99
Kunik102
Kunik101
Lamers103
Livermore104
Jang69
Walters67
Subtotal (l2=81.4%, P=0.000)
Self-management education 
Bucknall87
Emery93,a
McGeoch107
Sassi-Dambron110
Taylor112
Subtotal (l2=48.1%, P=0.103)
−0.14 (−0.43, 0.15)
0.36 (−0.21, 0.93)
0.26 (−0.06, 0.58)
−0.11 (−0.56, 0.33)
−0.35 (−0.79, 0.09)
−0.01 (−0.25, 0.24)
Multi-component exercise training
de Godoy89
Effing91
Elçi92
Emery93,b
Griffiths95
Güell96
Kayahan100
Lolak105
Özdemir108
Paz-Díaz109
Spencer111
Gurgun65,c
Gurgun65,d
Wadell66
Subtotal (l2=55.4%, P=0.006)
Relaxation
Donesky-Cuenco90
Gift94
Lord106
Intervention
−2 −1.5 −1 −0.5 0 0.5 1 1.5 2
Control
Subtotal (l2=0.0%, P=0.945)
Note: Weights are from random effects analysis
0.16 (−0.20, 0.52)
−0.53 (−1.08, 0.03)
0.36(−0.57, 1.30)
0.07 (−0.50, 0.64)
−0.11 (−0.46, 0.25)
−0.12 (−0.46, 0.23)
−0.71 (−1.35, −0.08)
−1.54 (−2.00, −1.08)
−0.16 (−0.48, 0.15)
−0.30(−0.65, 0.05)
−0.73 (−1.48, 0.01)
−0.22 (−0.56, 0.13)
−1.58 (−2.09, −1.07)
−0.13 (−0.69, 0.42)
−0.38 (−0.67, −0.08)
−0.20 (−0.86, 0.47)
−0.50 (−1.10, 0.10)
0.09 (−0.53, 0.71)
−0.39 (−0.95, 0.17)
−0.79 (−1.63, 0.05)
−0.25 (−0.82, 0.32)
−0.52 (−1.40, 0.35)
−0.98 (−1.89, −0.07)
−0.22 (−0.84, 0.40)
−0.46 (−0.69, −0.23)
−0.13 (−0.86, 0.60)
−0.22 (−0.99, 0.55)
−0.31 (−1.06, 0.44)
−0.22 (−0.65, 0.21)
26.78
12.90
24.68
17.66
18.00
100.00
12.54
10.52
7.08
10.40
12.57
12.62
9.77
11.57
12.93
100.00
5.65
10.71
8.27
7.68
11.47
6.42
7.13
6.89
7.62
4.81
7.52
4.60
4.36
6.87
100.00
35.14
31.42
33.44
100.00
SMD (95% CI)
%
weight
Figure 2 effects of subgroups of complex interventions on self-reported anxiety at post-treatment.
Note: Random-effects model was used. aeducation and stress management; bexercise, education, and stress management; cindependent comparison 1, pulmonary rehabilitation 
and nutritional support; dindependent comparison 2, pulmonary rehabilitation.
Abbreviations: CBT, cognitive and behavioral therapy; CI, confidence interval; SMD, standardized mean difference.
interventions for common mental health problems in COPD 
patients attending pulmonary rehabilitation.
Interventions based on a CBT format are also poten-
tially effective for managing depression in COPD. These 
results are consistent with other meta-analyses showing that 
psychological interventions that include CBT significantly 
reduce symptoms of depression in people with long-term 
conditions.71,72 However, the size of the treatment effects 
associated with CBT in populations with long-term condi-
tions are small and possibly of trivial importance for patients. International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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Existing evidence about the beneficial effects of CBT in 
anxiety disorders73 and in other long-term conditions74 
implies that unique features of COPD might account for 
the relatively small treatment effects for CBT in this patient 
group. For instance, the use of CBT techniques to counter 
ruminative thinking and avoidance behaviors might not be 
acceptable to COPD patients when these behaviors are trig-
gered as a response to real and meaningful COPD symptoms 
such as dyspnea.62 Alternative or “third wave” psychological 
therapies that target the process of thoughts (rather than their 
content, as in CBT) and help people to become aware of their 
thoughts and accept them in a nonjudgmental way are equally 
effective for depression as CBT.75 Mindfulness meditation 
is associated with longer-term mental health benefits when 
compared with relaxation alone76 and is acceptable among 
people with long-term conditions,77 but its effectiveness 
among COPD patients has not yet been confirmed.78
Other explanations for why stand-alone interventions 
such as CBT may only confer modest benefits in people with 
COPD point to the need to embed psychological interventions 
within collaborative and multidisciplinary frameworks that 
promote proactive case management of patients and super-
vision of psychological therapists. Collaborative care is a 
complex intervention that typically involves a case manager 
working in conjunction with the patient’s physician (usually 
their primary care physician), often with the support and 
supervision of a mental health specialist (a psychiatrist or 
psychologist). When compared with usual care, collaborative 
care is associated with significant improvement in depres-
sion and anxiety outcomes over the short-, medium-, and 
long-term.75 There is also evidence that collaborative care 
can improve both physical and mental health in people with 
long-term conditions.79 However, there is less evidence that 
collaborative interventions are effective in COPD, and trials 
to date have focused on self-management interventions to 
reduce exacerbations and improve medication adherence in 
acute illness, not on reducing depression or anxiety.80,81
In this overview, we have focused on the benefits of non-
pharmacological interventions for the management of depres-
sion and anxiety in COPD. Psychological interventions are as 
effective as drug therapies for improving the psychological 
ill health of patients with COPD and are rated as preferable 
to drug therapies by patients.57,82 Additionally, psychological 
interventions with or without medication have been recom-
mended for managing depression and anxiety in COPD.55 To 
date, the levels of evidence for the efficacy of pharmacological 
interventions in reducing depression and anxiety in COPD are 
limited. Two recent reviews suggested that no firm   conclusions 
can be drawn about the effectiveness of antidepressants 
(selective serotonin reuptake inhibitors and tricyclic antide-
pressants) in reducing depression in COPD because there are 
only a small number of published trials in this area, many of 
which have important methodological limitations, such as 
small sample sizes, and high dropout rates.83,84
Conclusion and future directions
There is ample research evidence that depression and anxiety 
are important determinants of health outcomes and health 
care utilization in COPD. Health care policy has highlighted 
the need to manage depression and anxiety in long-term con-
ditions, including COPD, but finding effective and innovative 
ways of implementing existing treatments remains a major 
challenge. Contemporary research suggests that complex 
psychological and/or lifestyle interventions which include a 
pulmonary rehabilitation component have the greatest effects 
on depression and anxiety in patients with COPD. However, 
further work is needed to understand how exercise improves 
anxious and depressed moods in COPD. Additionally, CBT 
appears to be effective in improving depression in COPD, 
but its benefits could be enhanced if embedded within col-
laborative care models that integrate physical and mental 
health care. Collaborative care models that focus on building 
partnerships between mental health and other professionals to 
foster integration of care for people with complex morbidities 
present a fruitful framework for the management of mental 
health in COPD. In particular, the integration of pulmonary 
rehabilitation and psychological therapies such as CBT has 
the potential to lead to significant patient benefits. Moreover, 
further research into ways to target markers of psychological 
health such as HRQoL could advance the clinical manage-
ment of mental health in COPD.
In conclusion, finding ways to strengthen the delivery of 
effective mental health care within the context of innovative 
chronic disease management programs such as pulmonary 
rehabilitation in primary care offer opportunities to meet the 
challenge set out by the World Health Organization that there 
can be “no health without mental health”.85
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